Characteristic | All patients (N = 45) | 30-day all-cause mortality group (N = 12) | Survival group (N = 33) | P-value† |
---|---|---|---|---|
Vancomycin trough concentration (μg/mL)a | 15 (9.7–22.3) | 20.5 (13.4–26.7) | 14.6 (9.3–19.2) | 0.022i) |
Frequency of vancomycin administration until the first measurement of the vancomycin trough concentrationa | 3 (3–5) | 3 (3–5) | 3 (3–5) | 0.36i) |
Vancomycin AUC24 (μg/mL·h)a | 665 (444–898) | 721 (380–860) | 651 (462–952) | 0.77i) |
Vancomycin AUC24/MIC ratioa | 725 (450–1186) | 792 (332–1040) | 707 (450–1304) | 0.76i) |
Number of cases with failure to achieve a vancomycin AUC24/MIC ratio ≤ 389 | 8 (17.8%) | 3 (25.0%) | 5 (15.2%) | 0.66ii) |
Duration of vancomycin administration (days)a | 11.5 (7.0–16.5) | 7 (4.0–11) | 15 (10–25) | < 0.001i) |
End of vancomycin administration due to death | 8 | 8 | 0 | – |
Vancomycin used for empirical therapy | 29 (64.4%) | 9 (75.0%) | 20 (60.6%) | 0.49ii) |
Duration from blood culture collection to vancomycin administration (days)a | 3 (1–4) | 1 (1–4) | 3 (1–4) | 0.30i) |